FTS3-01-04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE

Authors :: Paul S. Aisen
John Thipphawong
Keith Karcher
Karin Ernstrom
Hartmuth C. Kolb
Rema Raman
Gary Romano
Ziad S. Saad
Michael C. Donohue
Robert H. Brashear
Nandini Raghavan
Yevgen Tymofyeyev
Gerald Novak
Yingqi Shi
Reisa A. Sperling
David Henley
Source :: Alzheimer's & Dementia. 15:P873-P874
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
medicine.medical_specialty
Epidemiology
Double blinded
business.industry
Health Policy
Disease
Placebo
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Developmental Neuroscience
Internal medicine
medicine
Biomarker (medicine)
Neurology (clinical)
Geriatrics and Gerontology
business

Tools